Two days after showing strong pediatric cancer data, Day One taps $150M in public capital
Public biotechs can still raise money, but it comes with a big caveat: The clinical data must impress.
It appears the market reacted so with Day One Biopharmaceuticals, as the biotech plans to secure $150 million this week in a public offering. The four-year-old company is following a trend of biotechs going straight to the market hours or days after releasing results that outperform expectations and pad the case for a drug’s potential regulatory path.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.